Disc Medicine, Inc. announced positive interim results from its Phase 1b clinical trial of DISC-0974 for chronic kidney disease, showing over 75% reduction in hepcidin and significant increases in hemoglobin levels compared to placebo. The trial demonstrated acceptable safety and tolerability across all dose levels.